CIK: 0001704132 · Show all filings
Period: Q2 2018 (← Previous) (Next →)
Filing Date: Aug 14, 2018
Total Value ($000): $293,368 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| INSM | Insmed Incorporated | 1,800,587 | $42,584 | 14.5% | $27.89 | -7.7% | COM | 457669307 |
| — | Biohaven Pharmaceutical Holding Company Ltd. | 851,200 | $33,639 | 11.5% | $26.07 | — | COM | G11196105 |
| — | Immunomedics, Inc. | 1,231,543 | $29,151 | 9.9% | $17.13 | — | COM | 452907108 |
| — | Myokardia, Inc. | 565,755 | $28,090 | 9.6% | $45.40 | — | COM | 62857M105 |
| — | CymaBay Therapeutics, Inc. | 2,023,369 | $27,154 | 9.3% | $9.20 | — | COM | 23257D103 |
| — | OptiNose, Inc. | 928,545 | $25,981 | 8.9% | $23.29 | — | COM | 68404V100 |
| RYTM | Rhythm Pharmaceuticals, Inc. | 721,903 | $22,567 | 7.7% | $27.09 | +0.9% | COM | 76243J105 |
| ABUS | Arbutus Biopharma Corporation | 2,651,825 | $19,358 | 6.6% | $5.62 | +6.0% | COM | 03879J100 |
| ASND | Ascendis Pharma A/S | 270,424 | $17,989 | 6.1% | $40.06 | — | SPONSORED ADR | 04351P101 |
| — | Alder BioPharmaceuticals, Inc. | 1,130,919 | $17,869 | 6.1% | $13.27 | — | COM | 014339105 |
| ACRS | Aclaris Therapeutics, Inc. | 529,551 | $10,575 | 3.6% | $22.18 | -16.7% | COM | 00461U105 |
| — | Alder BioPharmaceuticals, Inc. | 350,000 | $5,530 | 1.9% | — | — | Put | 014339955 |
| — | Eidos Therapeutics, Inc. | 245,082 | $4,985 | 1.7% | $20.34 | — | COM | 28249H104 |
| RCUS | Arcus Biosciences, Inc. | 295,000 | $3,611 | 1.2% | $16.66 | -5.8% | COM | 03969F109 |
| — | Tricida, Inc. | 75,000 | $2,243 | 0.8% | $29.91 | — | COM | 89610F101 |
| — | Kiniksa Pharmaceuticals, Ltd. | 94,477 | $1,639 | 0.6% | $17.35 | — | Class A Common | G5269C101 |
| QURE | uniQure N.V. | 10,650 | $403 | 0.1% | $15.23 | +110.3% | SHS | N90064101 |